<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02324517</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-09-7563-GK-CTIL</org_study_id>
    <nct_id>NCT02324517</nct_id>
  </id_info>
  <brief_title>Ex Vivo Laboratory Assays Application for Therapy Tailoring in Patients With Severe Bleeding Disorders</brief_title>
  <official_title>Ex Vivo Laboratory Assays Application for Therapy Tailoring in Patients With Severe Bleeding Disorders, Including Hemophilia With Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Therapy of patients with severe hemophilia (including hemophilia with inhibitors) and other
      severe bleeding disorders could be monitored and guided based upon special clotting assays ,
      eg thrombin generation and thromboelastography. In this study blood sampled from patients
      with bleeding disorders will be evaluated applying ex- vivo spiking assays with various
      coagulation concentrates to potentially address the feasibility of replacement /bypass
      agents/ combined therapy for future bleeding episodes. Patients that will be further treated
      by any regimen potentially suggested (as standard care- not within trial) will be thereafter
      followed , including repeated lab studies to assess the impact of therapy upon hemostasis.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2010</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Thrombin Generation Parameters pre and post therapy / spiking assays</measure>
    <time_frame>1 year from enrollment</time_frame>
    <description>Thrombin Generation Parameters (Peak height, ETP) before and after spiking assays with procoagulant drugs will be compared for each patient separately and within each group of patients diagnosed with similar coagulation disorder.</description>
  </primary_outcome>
  <number_of_groups>10</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Severe Hemophilia</condition>
  <arm_group>
    <arm_group_label>Hemophilia</arm_group_label>
    <description>Patients with Hemophilia A OR B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>inhibitor patients</arm_group_label>
    <description>Hemophilia or FXI def with inhibitors</description>
  </arm_group>
  <arm_group>
    <arm_group_label>anticoagulants</arm_group_label>
    <description>patients under therapy with various anticoagulant drugs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>thrombocytopenia</arm_group_label>
    <description>patients with ITP, chronic thrombocytopenia, chemotherapy induced thrombocytopenia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>platelet function disorders</arm_group_label>
    <description>Glanzmann, Bernard Soulier, antiplatelet therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fibrinogen disordsers</arm_group_label>
    <description>hyperfibrinogenemia, hypofibrinogenemia, dysfibrinogenemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>acquired hemophilia</arm_group_label>
    <description>patients with autoimmune Ab's to FVIII</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RBD</arm_group_label>
    <description>FXIII DEF, FV+FVIII DEF, FVII DEF, FV DEF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>THROMBOLYTICS</arm_group_label>
    <description>Patients treated by thrombolytic agents</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypercoag</arm_group_label>
    <description>thrombophilias, thrombosis- inc under therapy, acquired high thrombotic risk (eg: cancer)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        patients with coagulopathies (see brief description)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent

          -  Validated coagulation disorder

        Exclusion Criteria:

          -  Not consenting to participate

          -  Multiple coagulopathies and comorbidities
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gili Kenet, MD</last_name>
    <phone>+972526666385</phone>
    <email>gili.kenet@sheba.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sheba Mediacl Center</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GITA VEIBER</last_name>
      <email>Gita.veiber@sheba.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Gili Kenet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2014</study_first_submitted>
  <study_first_submitted_qc>December 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2014</study_first_posted>
  <last_update_submitted>December 18, 2014</last_update_submitted>
  <last_update_submitted_qc>December 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheba Medical Center</investigator_affiliation>
    <investigator_full_name>Prof. Gila Kenet MD</investigator_full_name>
    <investigator_title>Director- Thrombosis Unit</investigator_title>
  </responsible_party>
  <keyword>response to various potential therapies as managed by lab assays</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

